Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction

被引:281
作者
Taussig, David C. [1 ,2 ]
Vargaftig, Jacques [1 ]
Miraki-Moud, Farideh [2 ]
Griessinger, Emmanuel [1 ]
Sharrock, Kirsty [3 ]
Luke, Tina [3 ]
Lillington, Debra [2 ]
Oakervee, Heather [2 ]
Cavenagh, Jamie [2 ]
Agrawal, Samir G. [2 ]
Lister, T. Andrew [2 ]
Gribben, John G. [2 ]
Bonnet, Dominique [1 ]
机构
[1] Canc Res UK London Res Inst, Haematopoiet Stem Cell Lab, London WC2A 3PX, England
[2] Queen Mary Univ London, St Bartholomews Hosp, Canc Res UK Med Oncol Unit, London, England
[3] Canc Res UK London Res Inst, FACS Lab, London WC2A 3PX, England
关键词
HEMATOPOIETIC STEM-CELLS; ACUTE MYELOGENOUS LEUKEMIA; NPM1; MUTATIONS; CYTOPLASMIC NUCLEOPHOSMIN; NORMAL KARYOTYPE; BONE-MARROW; PROGENITOR CELLS; ADULT PATIENTS; IN-VIVO; AML;
D O I
10.1182/blood-2009-02-206565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leukemia-initiating cells (LICs) in acute myeloid leukemia (AML) are believed to be restricted to the CD34(+) fraction. However, one of the most frequently mutated genes in AML is nucleophosmin (NPM), and this is associated with low CD34 expression. We, therefore, investigated whether NPM-mutated AMLs have LICs restricted to the CD34(+) fraction. We transplanted sorted fractions of primary NPM-mutated AML into immunodeficient mice to establish which fractions initiate leukemia. Approximately one-half of cases had LICs exclusively within the CD34(-) fraction, whereas the CD34(-) fraction contained normal multilineage hematopoietic repopulating cells. Most of the remaining cases had LICs in both CD34(-) and CD34(-) fractions. When samples were sorted based on CD34 and CD38 expression, multiple fractions initiated leukemia in primary and secondary recipients. The data indicate that the phenotype of LICs is more heterogeneous than previously realized and can vary even within a single sample. This feature of LICs may make them particularly difficult to eradicate using therapies targeted against surface antigens. (Blood. 2010; 115: 1976-1984)
引用
收藏
页码:1976 / 1984
页数:9
相关论文
共 34 条
[1]   Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines [J].
Ailles, LE ;
Gerhard, B ;
Hogge, DE .
BLOOD, 1997, 90 (07) :2555-2564
[2]   Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance [J].
Alcalay, M ;
Tiacci, E ;
Bergomas, R ;
Bigerna, B ;
Venturini, E ;
Minardi, SP ;
Meani, N ;
Diverio, D ;
Bernard, L ;
Tizzoni, L ;
Volorio, S ;
Luzi, L ;
Colombo, E ;
Lo Coco, F ;
Mecucci, C ;
Falini, B ;
Pelicci, PG .
BLOOD, 2005, 106 (03) :899-902
[3]   Modeling the initiation and progression of human acute leukemia in mice [J].
Barabe, Frederic ;
Kennedy, James A. ;
Hope, Kristin J. ;
Dick, John E. .
SCIENCE, 2007, 316 (5824) :600-604
[4]   A newly discovered class of human hematopoietic cells with SCID-repopulating activity [J].
Bhatia, M ;
Bonnet, D ;
Murdoch, B ;
Gan, OI ;
Dick, JE .
NATURE MEDICINE, 1998, 4 (09) :1038-1045
[5]   Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR- [J].
Blair, A ;
Hogge, DE ;
Sutherland, HJ .
BLOOD, 1998, 92 (11) :4325-4335
[6]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[7]   Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations [J].
Chou, W-C ;
Tang, J-L ;
Wu, S-J ;
Tsay, W. ;
Yao, M. ;
Huang, S-Y ;
Huang, K-C ;
Chen, C-Y ;
Huang, C-F ;
Tien, H-F .
LEUKEMIA, 2007, 21 (05) :998-1004
[8]   Nucleophosmin mutations in De novo acute myeloid leukemia:: The age-dependent incidences and the stability during disease [J].
Chou, WC ;
Tang, JL ;
Lin, LI ;
Yao, M ;
Tsay, W ;
Chen, CY ;
Wu, SJ ;
Huang, CF ;
Chiou, RJ ;
Tseng, MH ;
Lin, DT ;
Lin, KH ;
Chen, YC ;
Tien, HF .
CANCER RESEARCH, 2006, 66 (06) :3310-3316
[9]   Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. [J].
Falini, B ;
Mecucci, C ;
Tiacci, E ;
Alcalay, M ;
Rosati, R ;
Pasqualucci, L ;
La Starza, R ;
Diverio, D ;
Colombo, E ;
Santucci, A ;
Bigerna, B ;
Pacini, R ;
Pucciarini, A ;
Liso, A ;
Vignetti, M ;
Fazi, P ;
Meani, N ;
Pettirossi, V ;
Saglio, G ;
Mandelli, F ;
Lo-Coco, F ;
Pelicci, P ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :254-266
[10]   Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice [J].
Falini, Brunangelo ;
Martelli, Maria Paola ;
Mecucci, Cristina ;
Liso, Arcangelo ;
Bolli, Niccolo ;
Bigerna, Barbara ;
Pucciarini, Alessandra ;
Pileri, Stefano ;
Meloni, Giovanna ;
Martelli, Massimo F. ;
Haferlach, Torsten ;
Schnittger, Susanne .
HAEMATOLOGICA, 2008, 93 (05) :775-779